Want to see AU:ALC full AI Analyst Report?
Alcidion Group Limited (ALC) Price & Analysis
ALC Stock Chart & Stats
- Day’s Range
- AUD 0.11 - AUD 0.12
- 52-Week Range
- AUD 0.08 - AUD 0.15
- Previous Close
- AUD 0.12
- Volume
- 2.06M
- Average Volume (3M)
- 947.08K
- Market Cap
- AUD 148.48M
- Enterprise Value
- AUD 121.20M
- Total Cash (Recent Filing)
- AUD 20.64M
- Total Debt (Recent Filing)
- AUD 814.00K
- Price to Earnings (P/E)
- 64.7
- Beta
- 0.91
- Next Earnings
- Feb 25, 2027
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Very Low Leverage
Extremely low leverage gives Alcidion substantial financial flexibility and minimizes refinancing and interest burdens. This conservative capital structure can support continued investment in healthcare software, help absorb operating volatility, and reduce balance-sheet pressure as the business pursues growth.
Positive Cash Generation
Positive operating and free cash flow in both 2025 and 2026 indicates that recent earnings are converting into internally generated funding. This supports product investment and day-to-day resilience without reliance on substantial external financing, despite some year-to-year variability.
Return To Growth And Earnings
The return to positive earnings alongside renewed revenue growth marks a meaningful improvement from earlier loss-making periods. Continued adoption of clinical information software could provide a foundation for operating leverage and more durable earnings generation if growth persists.
Bears Say
Modest Profitability
Despite the return to profitability, Alcidion is retaining only a modest share of revenue as profit. Thin margins leave less room to absorb cost increases or execution setbacks and may limit the pace at which the company can reinvest in products, sales, and platform development.
Earnings Volatility
The recent history of sizable losses followed by a return to profit shows that earnings remain uneven rather than firmly established. This volatility makes sustainable profitability harder to demonstrate and increases the risk that future operating performance could fluctuate materially.
Variable Cash Conversion
Recent cash generation is positive, but the decline in 2026 and negative operating and free cash flow in 2024 indicate inconsistent cash conversion through the cycle. Such variability can constrain predictable funding for expansion and makes internally financed growth less dependable.
Alcidion Group Limited News
ASX drops quarterly cash flow reporting for financially strengthened Alcidion
Alcidion Group Limited ( ($AU:ALC) ) has issued an announcement. Healthcare technology provider Alcidion Group Limited has secured relief from the Australian Securities Exchange’s requirement to lodge quarterly cash flow
ALC FAQ
What was Alcidion Group Limited’s price range in the past 12 months?
What is Alcidion Group Limited’s market cap?
When is Alcidion Group Limited’s upcoming earnings report date?
How were Alcidion Group Limited’s earnings last quarter?
Is Alcidion Group Limited overvalued?
Does Alcidion Group Limited pay dividends?
What is Alcidion Group Limited’s EPS estimate?
How many shares outstanding does Alcidion Group Limited have?
What happened to Alcidion Group Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Alcidion Group Limited?
What is the TipRanks Smart Score and how is it calculated?
Alcidion Group Limited Stock Smart Score
Company Description
Alcidion Group Limited
Alcidion Group Limited operates as a healthcare technology firm, specializing in the creation and licensing of software products across Australia, New Zealand, and the United Kingdom. Its flagship product, Miya Precision, is a consolidated platform built on the Fast Healthcare Interoperability Resources (FHIR) standard, aimed at enabling intelligent healthcare delivery. The company also supplies Smartpage, a mobile and web-based system designed to streamline hospital communications and task management for clinical and administrative personnel. Additional solutions include Patientrack, a tool for real-time patient monitoring and risk screening; Silverlink, which handles patient administration; and ExtraMed, software dedicated to optimizing clinical and patient flow. Furthermore, Alcidion provides a range of services encompassing product deployment, support and maintenance, systems integration, and data analysis. Founded in 2000 and headquartered in South Yarra, Australia, the company was formerly known as Alcidion Corporation Pty Ltd until its rebranding as Alcidion Group Limited in December 2015.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Kate Quirke
- Employees
- 141
- Website
- www.alcidion.com
- Address
- 9 Yarra Street, South Yarra, VIC, 3141, AU
Alcidion Group Limited (ALC) Earnings & Revenues
ALC Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 2 | 6 |
| Technical Analysis | 4 | 2 | 4 |
| Moving Averages | 10 | 0 | 2 |







